Probiotic mixture VSL#3 reduce high fat diet induced vascular inflammation and atherosclerosis in ApoE−/− mice

AMB Express

Volumn 6, Issue 1, 2016, Pages

  Chan, Yee Kwan ^a   El Nezami, Hani ^a,b   Chen, Yan ^c   Kinnunen, Kristiina ^b   Kirjavainen, Pirkka V ^b,d  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF EASTERN FINLAND   (Finland)

^c UNIVERSITY OF HONG KONG   (Hong Kong)

^d NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

Author keywords

Atherosclerosis; Gut microbiota; Vascular inflammation; VSL 3

Indexed keywords

ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FIBRINOGEN; GELATINASE B; GLUCAGON LIKE PEPTIDE 1; INTERCELLULAR ADHESION MOLECULE 1; MONOCYTE CHEMOTACTIC PROTEIN 1; PANCREAS POLYPEPTIDE; PEPTIDE YY; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROBIOTIC AGENT; TELMISARTAN; TUMOR NECROSIS FACTOR; VASCULAR CELL ADHESION MOLECULE 1; VSL3;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATHEROSCLEROSIS; BACTERIAL TRANSLOCATION; BIFIDOBACTERIUM BREVE; BIFIDOBACTERIUM INFANTIS; BIFIDOBACTERIUM LONGUM; CARDIOVASCULAR RISK; CONTROLLED STUDY; DNA ISOLATION; FEMALE; FOOD INTAKE; INTESTINE FLORA; LACTOBACILLUS ACIDOPHILUS; LACTOBACILLUS DELBRUECKII SUBSP. BULGARICUS; LACTOBACILLUS PARACASEI; LACTOBACILLUS PLANTARUM; LIPID DIET; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; STREPTOCOCCUS THERMOPHILUS; VASCULITIS; WEIGHT CHANGE;

EID: 84984891635     PISSN: None     EISSN: 21910855     Source Type: Journal    
DOI: 10.1186/s13568-016-0229-5     Document Type: Article

References (41)

1. Baglione J, Smith JD. Quantitative assay for mouse atherosclerosis in the aortic root. Methods Mol Med. 2006;129:83–95. doi:10.1152/ajpendo.90617.2008.
2. Bian C, Wu Y, Chen P. Telmisartan increases the permeability of endothelial cells through zonula occludens-1. Biol Pharm Bull. 2009;32:416–20.
3. Blessing E, Preusch M, Kranzhofer R, Kinscherf R, Marx N, Rosenfeld ME, Isermann B, Weber CM, Kreuzer J, Grafe J, Katus HA, Bea F. Anti-atherosclerotic properties of telmisartan in advanced atherosclerotic lesions in apolipoprotein E deficient mice. Atherosclerosis. 2008;199:295–303. doi:10.1016/j.atherosclerosis.2007.10.037.
4. Cani PD, Delzenne NM, Amar J, Burcelin R. Role of gut microflora in the development of obesity and insulin resistance following high-fat diet feeding. Pathol Biol. 2008;56:305–9. doi:10.1016/j.patbio.2007.09.008.
5. Dhiman RK, Rana B, Agrawal S, Garg A, Chopra M, Thumburu KK, Khattri A, Malhotra S, Duseja A, Chawla YK. Probiotic VSL#3 reduces liver disease severity and hospitalization in patients with cirrhosis: a randomized, controlled trial. Gastroenterology. 2014;147(1327–1337):e1323. doi:10.1053/j.gastro.2014.08.031.
6. Fak F, Backhed F. Lactobacillus reuteri prevents diet-induced obesity, but not atherosclerosis, in a strain dependent fashion in Apoe-/- mice. PLoS ONE. 2012;7:e46837. doi:10.1371/journal.pone.0046837.
7. Fedorak RN, Feagan BG, Hotte N, Leddin D, Dieleman LA, Petrunia DM, Enns R, Bitton A, Chiba N, Pare P, Rostom A, Marshall J, Depew W, Bernstein CN, Panaccione R, Aumais G, Steinhart AH, Cockeram A, Bailey RJ, Gionchetti P, Wong C, Madsen K. The probiotic VSL#3 has anti-inflammatory effects and could reduce endoscopic recurrence after surgery for Crohn’s disease clinical gastroenterology and hepatology: the official clinical practice. J Am Gastroenterol Assoc. 2015;13:928–35. doi:10.1016/j.cgh.2014.10.031.
8. Guo Z, Liu XM, Zhang QX, Shen Z, Tian FW, Zhang H, Sun ZH, Zhang HP, Chen W. Influence of consumption of probiotics on the plasma lipid profile: a meta-analysis of randomised controlled trials. Nutr Metab Cardiovasc Dis. 2011;21:844–50. doi:10.1016/j.numecd.2011.04.008.
9. Hasegawa H, Takano H, Narumi H, Ohtsuka M, Mizuguchi T, Namiki T, Kobayashi Y, Komuro I. Effects of telmisartan and losartan on cardiovascular protection in Japanese hypertensive patients hypertension research: official journal of the Japanese Society of. Hypertension. 2011;34:1179–84. doi:10.1038/hr.2011.114.
10. Karlsson C, Ahrne S, Molin G, Berggren A, Palmquist I, Fredrikson GN, Jeppsson B. Probiotic therapy to men with incipient arteriosclerosis initiates increased bacterial diversity in colon: a randomized controlled trial. Atherosclerosis. 2010;208:228–33. doi:10.1016/j.atherosclerosis.2009.06.019.
11. Karlsson FH, Fak F, Nookaew I, Tremaroli V, Fagerberg B, Petranovic D, Backhed F, Nielsen J. Symptomatic atherosclerosis is associated with an altered gut metagenome. Nat Commun. 2012;3:1245. doi:10.1038/ncomms2266.
12. Kekkonen RA, Lummela N, Karjalainen H, Latvala S, Tynkkynen S, Jarvenpaa S, Kautiainen H, Julkunen I, Vapaatalo H, Korpela R. Probiotic intervention has strain-specific anti-inflammatory effects in healthy adults. World J Gastroenterol. 2008;14:2029–36.
13. Kolida S, Tuohy K, Gibson GR. Prebiotic effects of inulin and oligofructose. Br J Nutr. 2002;87(Suppl 2):S193–7. doi:10.1079/BJNBJN/2002537.
14. Koren O, Spor A, Felin J, Fak F, Stombaugh J, Tremaroli V, Behre CJ, Knight R, Fagerberg B, Ley RE, Backhed F. Human oral, gut, and plaque microbiota in patients with atherosclerosis. Proc Natl Acad Sci USA. 2010;108(Suppl 1):4592–8. doi:10.1073/pnas.1011383107.
15. Koren O, Spor A, Felin J, Fak F, Stombaugh J, Tremaroli V, Behre CJ, Knight R, Fagerberg B, Ley RE, Backhed F. Human oral, gut, and plaque microbiota in patients with atherosclerosis. Proc Natl Acad Sci USA. 2011;108(Suppl 1):4592–8. doi:10.1073/pnas.1011383107.
16. Kruszewska H, Zareba T, Tyski S. Search of antimicrobial activity of selected non-antibiotic drugs. Acta Pol Pharm. 2002;59:436–9.
17. Kuhbacher T, Ott SJ, Helwig U, Mimura T, Rizzello F, Kleessen B, Gionchetti P, Blaut M, Campieri M, Folsch UR, Kamm MA, Schreiber S. Bacterial and fungal microbiota in relation to probiotic therapy (VSL#3) in pouchitis. Gut. 2006;55:833–41. doi:10.1136/gut.2005.078303.
18. Lievin V, Peiffer I, Hudault S, Rochat F, Brassart D, Neeser JR, Servin AL. Bifidobacterium strains from resident infant human gastrointestinal microflora exert antimicrobial activity. Gut. 2000;47:646–52.
19. Lopez-Mejias R, Genre F, Garcia-Bermudez M, Ubilla B, Castaneda S, Llorca J, Gonzalez-Juanatey C, Corrales A, Miranda-Filloy JA, Pina T, Gomez-Vaquero C, Rodriguez-Rodriguez L, Fernandez-Gutierrez B, Balsa A, Pascual-Salcedo D, Lopez-Longo FJ, Carreira P, Blanco R, Martin J, Gonzalez-Gay MA. Lack of association between ABO, PPAP2B, ADAMST7, PIK3CG, and EDNRA and carotid intima-media thickness, carotid plaques, and cardiovascular disease in patients with rheumatoid arthritis. Mediators Inflamm. 2014;2014:756279. doi:10.1155/2014/756279.
20. Lye HS, Kuan CY, Ewe JA, Fung WY, Liong MT. The improvement of hypertension by probiotics: effects on cholesterol, diabetes, renin, and phytoestrogens. Int J Mol Sci. 2009;10:3755–75. doi:10.3390/ijms10093755.
21. Mardini HE, Grigorian AY. Probiotic mix VSL#3 is effective adjunctive therapy for mild to moderately active ulcerative colitis: a meta-analysis. Inflamm Bowel Dis. 2014;20:1562–7. doi:10.1097/MIB.0000000000000084.
22. Martin RM, Ebrahim S, Griffin M, Davey Smith G, Nicolaides AN, Georgiou N, Watson S, Frankel S, Holly JM, Gunnell D. Breastfeeding and atherosclerosis: intima-media thickness and plaques at 65-year follow-up of the Boyd Orr cohort. Arterioscler Thromb Vasc Biol. 2005;25:1482–8. doi:10.1161/01.ATV.0000170129.20609.49.
23. Matsumura T, Kinoshita H, Ishii N, Fukuda K, Motoshima H, Senokuchi T, Taketa K, Kawasaki S, Nishimaki-Mogami T, Kawada T, Nishikawa T, Araki E. Telmisartan exerts antiatherosclerotic effects by activating peroxisome proliferator-activated receptor-gamma in macrophages. Arterioscler Thromb Vasc Biol. 2011;31:1268–75. doi:10.1161/ATVBAHA.110.222067.
24. Meir KS, Leitersdorf E. Atherosclerosis in the apolipoprotein-E-deficient mouse: a decade of progress. Arterioscler Thromb Vasc Biol. 2004;24:1006–14. doi:10.1161/01.ATV.0000128849.12617.f4.
25. Mencarelli A, Cipriani S, Renga B, Bruno A, D’Amore C, Distrutti E, Fiorucci S. VSL#3 resets insulin signaling and protects against NASH and atherosclerosis in a model of genetic dyslipidemia and intestinal inflammation. PLoS ONE. 2012a;7:e45425. doi:10.1371/journal.pone.0045425.
26. Mencarelli A, Cipriani S, Renga B, Bruno A, D’Amore C, Distrutti E, Fiorucci S. VSL#3 resets insulin signaling and protects against NASH and atherosclerosis in a model of genetic dyslipidemia and intestinal inflammation. PLoS ONE. 2012b;9:e45425.
27. Mennigen R, Bruewer M. Effect of probiotics on intestinal barrier function. Ann N Y Acad Sci. 2009;1165:183–9. doi:10.1111/j.1749-6632.2009.04059.x.
28. Mercado C, Jaimes EA. Cigarette smoking as a risk factor for atherosclerosis and renal disease: novel pathogenic insights. Curr Hypertens Rep. 2007;9:66–72.
29. Munger MA. Use of angiotensin receptor blockers in cardiovascular protection: current evidence and future directions. PT. 2011;36:22–40.
30. Nase L, Hatakka K, Savilahti E, Saxelin M, Ponka A, Poussa T, Korpela R, Meurman JH. Effect of long-term consumption of a probiotic bacterium Lactobacillus rhamnosus GG, in milk on dental caries and caries risk in children. Caries Res. 2001;35:412–20.
31. Nubel U, Engelen B, Felske A, Snaidr J, Wieshuber A, Amann RI, Ludwig W, Backhaus H. Sequence heterogeneities of genes encoding 16S rRNAs in Paenibacillus polymyxa detected by temperature gradient gel electrophoresis. J Bacteriol. 1996;178:5636–43.
32. Randazzo CL, Vaughan EE, Caggia C. Artisanal and experimental Pecorino Siciliano cheese: microbial dynamics during manufacture assessed by culturing and PCR-DGGE analyses. Int J Food Microbiol. 2006;109:1–8. doi:10.1016/j.ijfoodmicro.2005.11.002.
33. Rault-Nania MH, Gueux E, Demougeot C, Demigne C, Rock E, Mazur A. Inulin attenuates atherosclerosis in apolipoprotein E-deficient mice. Br J Nutr. 2006;96:840–4.
34. Reagan-Shaw S, Nihai M, Ahmad N. Dose translation from animal to human studies revisited. FASEB J. 2008;22:659–61.
35. Sanaie S, Ebrahimi-Mameghani M, Mahmoodpoor A, Shadvar K, Golzari SE. Effect of a probiotic preparation (VSL#3) on cardiovascular risk parameters in critically-ill patients. J Cardiovasc Thorac Res. 2013;5:67–70. doi:10.5681/jcvtr.2013.014.
36. Sekirov I, Russell SL, Antunes LC, Finlay BB. Gut microbiota in health and disease. Physiol Rev. 2010;90:859–904. doi:10.1152/physrev.00045.2009.
37. Takaya T, Kawashima S, Shinohara M, Yamashita T, Toh R, Sasaki N, Inoue N, Hirata K, Yokoyama M. Angiotensin II type 1 receptor blocker telmisartan suppresses superoxide production and reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice. Atherosclerosis. 2006;186:402–10. doi:10.1016/j.atherosclerosis.2005.08.009.
38. Tedgui A, Mallat Z. Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev. 2006;86:515–81. doi:10.1152/physrev.00024.2005.
39. Velagapudi VR, Hezaveh R, Reigstad CS, Gopalacharyulu P, Yetukuri L, Islam S, Felin J, Perkins R, Boren J, Oresic M, Backhed F. The gut microbiota modulates host energy and lipid metabolism in mice. J Lipid Res. 2010;51:1101–12. doi:10.1194/jlr.M002774.
40. Wang Z, Klipfell E, Bennett BJ, Koeth R, Levison BS, Dugar B, Feldstein AE, Britt EB, Fu X, Chung YM, Wu Y, Schauer P, Smith JD, Allayee H, Tang WH, DiDonato JA, Lusis AJ, Hazen SL. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature. 2011;472:57–63. doi:10.1038/nature09922.
41. Warren TY, Barry V, Hooker SP, Sui X, Church TS, Blair SN. Sedentary behaviors increase risk of cardiovascular disease mortality in men. Med Sci Sports Exerc. 2010;42:879–85. doi:10.1249/MSS.0b013e3181c3aa7e.